Zimmer Biomet Q4 Revenue Seen Up 8.9% to $2.20B, EPS at $2.38
Zimmer Biomet’s Q4 revenue is forecast at $2.20 billion, up 8.9% year-over-year, with EPS estimated at $2.38, a 3% increase. Shares have slipped 15.3% this quarter versus a 10.8% industry decline, and the stock holds a Zacks Rank #3 with a –0.40% Earnings ESP.
1. Q4 Estimates and Growth Drivers
Zimmer Biomet is projected to report $2.20 billion in Q4 revenue, an 8.9% year-over-year increase, fueled by strong adoption of the Persona OsseoTi cementless knee system, expanded ROSA robotic surgical placements and continued momentum in its Hips and S.E.T. businesses. EPS are expected at $2.38, up 3% from the prior year, reflecting broad product portfolio gains.
2. Stock Performance and Analyst Outlook
Shares declined 15.3% in the quarter compared with a 10.8% drop for the medical device industry, indicating investor caution ahead of the earnings release. The company holds a Zacks Rank #3 (Hold) and carries a –0.40% Earnings ESP, signaling a low probability of an upside surprise to consensus estimates.